# Pantilogos

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pantilogos

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Total disclosed funding: $11M
- Latest round: Series A (Oct 29, 2021)
- Investors on record: 2

## About

Founded in 2020, and based in Seoul, South Korea, Pantilogos, a subsidiary of Eutilex Co., Ltd., is a biopharmaceutical company that develops anti-tumor cell and antibody therapeutics for the treatment of cancer and autoimmune diseases. In October 2021, Pantilogos raised KRW 13 billion in series A funding from DAYLI Partners, and Timeworks Investment.

The company is focused on the research and development of anti-tumor cell and antibody therapeutics aimed at treating cancer and autoimmune diseases. Leveraging advanced immunotherapy platforms, Pantilogos is working to develop novel biologics that target immune system pathways to enhance therapeutic efficacy and patient outcomes. Pantilogos’ product pipeline includes investigational therapies designed to modulate immune responses, with a focus on T-cell and antibody-based treatments. These therapies are intended to address unmet medical needs in oncology and immunology, offering potential alternatives to conventional treatments.

## Funding rounds

- Series A, Oct 29, 2021, $11M — DAYLI Partners, Timeworks Investment

## Investors

- DAYLI Partners (https://capitalatlas.ai/funds/dayli-partners) — Series A
- Timeworks Investment (https://capitalatlas.ai/funds/timeworks-investment) — Series A